Assembly Biosciences, Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +10.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.20 | not reported | not reported | |
| Q1 FY26 | $-0.73 | $-0.54 | +26.0% | Beat | |
| Q4 FY25 | not reported | $2.48 | not reported | not reported | |
| Q3 FY25 | $-0.50 | $-0.72 | -44.0% | Miss | |
| Q2 FY25 | not reported | $-1.33 | not reported | not reported | |
| Q1 FY25 | $-2.01 | $-1.17 | +41.8% | Beat | |
| Q4 FY24 | $-1.75 | $-1.57 | +10.3% | Beat | |
| Q3 FY24 | $-2.02 | $-1.51 | +25.3% | Beat | |
| Q2 FY24 | $-2.96 | $-1.98 | +33.1% | Beat | |
| Q1 FY24 | $-2.74 | $-1.66 | +39.4% | Beat | |
| Q3 FY23 | $-0.23 | $-0.27 | -17.4% | Miss | |
| Q2 FY23 | $-0.29 | $-0.32 | -10.3% | Miss |
Back to ASMB overview · ASMB holders · ASMB KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.